Northern Trust
CARM

Northern Trust’s Carisma Therapeutics CARM Stock Holding History

Northern Trust’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,039
Closed -$15.1K – 4465
2025
Q3 		$15.1K Hold
55,039
– – ﹤0.01% 4392
2025
Q2 		$21.6K Hold
55,039
– – ﹤0.01% 4328
2025
Q1 		$17.1K Sell
55,039
-14,849
-21% -$6.58K ﹤0.01% 4351
2024
Q4 		$29.3K Sell
69,888
-5,563
-7% -$4.58K ﹤0.01% 4337
2024
Q3 		$74.1K Sell
75,451
-148,907
-66% -$161K ﹤0.01% 4129
2024
Q2 		$341K Buy
224,358
+3,456
+2% +$5.16K ﹤0.01% 3647
2024
Q1 		$501K Sell
220,902
-18,014
-8% -$43.3K ﹤0.01% 3561
2023
Q4 		$700K Buy
238,916
+41,644
+21% +$124K ﹤0.01% 3430
2023
Q3 		$834K Sell
197,272
-21,104
-10% -$134K ﹤0.01% 3355
2023
Q2 		$1.92M Buy
218,376
+201,972
+1,231% +$1.1M ﹤0.01% 3033
2023
Q1 		$50.9K Sell
16,404
-2
-0% -$19 ﹤0.01% 4267
2022
Q4 		$200K Sell
16,406
-215
-1% -$2.26K ﹤0.01% 3876
2022
Q3 		$141K Hold
16,621
– – ﹤0.01% 4003
2022
Q2 		$269K Sell
16,621
-70,219
-81% -$803K ﹤0.01% 3771
2022
Q1 		$1.05M Sell
86,840
-3,023
-3% -$42.2K ﹤0.01% 3398
2021
Q4 		$1.47M Buy
89,863
+67
+0.1% +$1.35K ﹤0.01% 3380
2021
Q3 		$1.42M Buy
89,796
+5,439
+6% +$261K ﹤0.01% 3424
2021
Q2 		$7.79M Buy
84,357
+69,384
+463% +$4.42M ﹤0.01% 2547
2021
Q1 		$779K Buy
14,973
+3,223
+27% +$152K ﹤0.01% 3678
2020
Q4 		$317K Sell
11,750
-118
-1% -$2.99K ﹤0.01% 3844
2020
Q3 		$332K Buy
11,868
+732
+7% +$14.6K ﹤0.01% 3692
2020
Q2 		$160K Hold
11,136
– – ﹤0.01% 3813
2020
Q1 		$125K Buy
11,136
+2,834
+34% +$46.4K ﹤0.01% 3772
2019
Q4 		$173K Sell
8,302
-200
-2% -$4.6K ﹤0.01% 3822
2019
Q3 		$199K Buy
8,502
+1,983
+30% +$46.4K ﹤0.01% 3769
2019
Q2 		$195K Buy
6,519
+49
+0.8% +$1.47K ﹤0.01% 3832
2019
Q1 		$133K Sell
6,470
-1,661
-20% -$28.7K ﹤0.01% 3860
2018
Q4 		$231K Sell
8,131
-24
-0.3% -$765 ﹤0.01% 3766
2018
Q3 		$350K Buy
8,155
+92
+1% +$3.58K ﹤0.01% 3717
2018
Q2 		$315K Buy
8,063
+6,582
+444% +$290K ﹤0.01% 3719
2018
Q1 		$31K Buy
1,481
+451
+44% +$8.66K ﹤0.01% 4132
2017
Q4 		$17K Hold
1,030
– – ﹤0.01% 4165
2017
Q3 		$33K Hold
1,030
– – ﹤0.01% 4106
2017
Q2 		$32K Hold
1,030
– – ﹤0.01% 4131
2017
Q1 		$45K Buy
1,030
+131
+15% +$5.46K ﹤0.01% 4064
2016
Q4 		$34K Buy
899
+8
+0.9% +$352 ﹤0.01% 4045
2016
Q3 		$50K Buy
+891
New +$66.3K ﹤0.01% 4002
2015
Q3 		– Sell
-2,172
Closed -$122K – 4297
2015
Q2 		$122K Sell
2,172
-279
-11% -$39.4K ﹤0.01% 3905
2015
Q1 		$437K Buy
2,451
+69
+3% +$15.1K ﹤0.01% 3647
2014
Q4 		$566K Buy
2,382
+56
+2% +$12.6K ﹤0.01% 3517
2014
Q3 		$518K Buy
2,326
+1
+0% +$238 ﹤0.01% 3558
2014
Q2 		$612K Buy
2,325
+440
+23% +$109K ﹤0.01% 3544
2014
Q1 		$612K Buy
+1,885
New +$565K ﹤0.01% 3502

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Northern Trust's CARM Position: Q4 2025 in Review

Northern Trust sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 55,039 shares — an estimated $15.1K sold.

Northern Trust first reported a position in CARM in Q1 2014 and held it in 43 quarters. The position peaked at $7.79M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Northern Trust reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Northern Trust sold 55,039 Carisma Therapeutics shares in Q4 2025, an estimated $15.1K.
  • Northern Trust first reported a position in Carisma Therapeutics in Q1 2014 and held it in 43 quarters.
  • Northern Trust's Carisma Therapeutics position peaked at $7.79M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Northern Trust's 13F filing for Q4 2025, filed 17 Feb 2026.